<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RISPERIDONE</span><br/>(ris-per'i-done)<br/><span class="topboxtradename">Risperdal, </span><span class="topboxtradename">Risperdal M-TAB, </span><span class="topboxtradename">Risperdal Consta<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">antipsychotic</span>; <span class="classification">atypical</span><br/><b>Prototype: </b>Clozapine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets; 0.5 mg, 1 mg, 2 mg quick-dissolving tablets; 1 mg/mL solution; 25 mg, 37.5 mg, 50 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism is not well understood. Interferes with binding of dopamine to D<sub>2</sub>-interlimbic region of the brain, serotonin (5-HT<sub>2</sub>) receptors, and alpha-adrenergic receptors in the occipital cortex. It has low to moderate affinity for the other serotonin
         (5-HT) receptors and no affinity to nondopaminergic sites (e.g., cholinergic, muscarinic, or beta-adrenergic receptors).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective in controlling symptoms of schizophrenia as well as other psychotic symptoms.</p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction or elimination of psychotic symptoms in schizophrenia and related psychoses; treatment of bipolar disorder. Seems
         to improve negative symptoms such as apathy, blunted affect, and emotional withdrawal.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Management of patients with dementia-related psychotic symptoms. Adjunctive treatment of behavioral disturbances in patients
         with mental retardation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to risperidone; elderly with dementia-related psychosis; QT prolongation, Reye's syndrome, brain tumor, severe
         CNS depression, head trauma; suicidal ideation, tardive dyskinesia; sunlight (UV) exposure, tanning beds; pregnancy (category
         C), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults; arrhythmias, hypotension, breast cancer, blood dyscrasia, cardiac disorders, cerebrovascular disease, hypotension,
         dehydration, diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hypokalemia, hypomagnesemia, hyponatremia, MI, obesity,
         orthostatic hypotension, mild or moderate CNS depression, coma; GI obstruction, dysphagia; electrolyte imbalance, ethanol
         intoxication, heart failure, renal or hepatic dysfunction; seizure disorder, seizures, stroke, Parkinson's disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Psychosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 16 mg b.i.d., start with 1 mg b.i.d., increase by 1 mg b.i.d. daily to an initial target dose of 3 mg b.i.d. (max: 8
               mg/d) <span class="rdroute">IM</span> 25 mg once q2wk (max: 50 mg)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 0.5 mg b.i.d. and increase by 0.5 mg b.i.d. daily to an initial target of 1.5 mg b.i.d. (max: 4 mg/d) <span class="rdroute">IM</span> 25 mg once q2wk (max: 25 mg)<br/><br/><span class="indicationtitle">Bipolar Disorder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 23 mg once daily for up to 3 wk<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 0.5 mg b.i.d. and increase by 0.5 mg b.i.d. daily to an initial target of 1.5 mg b.i.d. (max: 4 mg/d). May convert
               to once daily dosing after stabilized in b.i.d. 23 d<br/><br/><span class="indicationtitle">Dementia-Related Psychotic Symptoms</span><br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 0.5 mg b.i.d., increase by 0.5 mg b.i.d. daily to an initial target of 1 mg b.i.d. (max: 2 mg/d)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that quick-dissolving tablets dissolve rapidly when placed on tongue.</li>
<li>Do not exceed increases/decreases of 1 mg b.i.d. in normal populations or 0.5 mg b.i.d. in older adults or the debilitated
            during dosage adjustments.
         </li>
<li>Make further increases at 1-wk or longer intervals after the target dose of 3 mg b.i.d. in normal populations and 1.5 mg b.i.d.
            in older adults or the debilitated are reached.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute the 25, 37.5, or 50 mg vial using the supplied 2 mL prefilled syringe. Shake vigorously for at least 10 sec to
            produce a uniform, thick, milky suspension. If 2 min or more pass before injection, shake vial again.
         </li>
<li>Give deep IM into the upper-outer quadrant of the gluteal muscle with the supplied needle; do not substitute. Follow the manufacturer's
            instructions for use of the SmartSite Needle-Free Vial Access Device and Needle-Pro device.
         </li>
<li>Store unopened vials at 2°8° C (36°46° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Orthostatic hypotension with initial doses, sweating, weakness, fatigue. <span class="typehead">CNS:</span>
<span class="speceff-common">Sedation, drowsiness, headache,</span> transient blurred vision, <span class="speceff-common">insomnia,</span> disinhibition, <span class="speceff-common">agitation,</span> anxiety, increased dream activity, dizziness, catatonia, <span class="speceff-common">extrapyramidal symptoms</span> (akathisia, dystonia, pseudoparkinsonism), especially with doses &gt;10 mg/d, <span class="speceff-life">neuroleptic malignant syndrome</span> (rare), increased risk of stroke in elderly. <span class="typehead">CV:</span> Prolonged QTc interval, tachycardia. <span class="typehead">GI:</span> Dry mouth, dyspepsia, nausea, vomiting, diarrhea, constipation, abdominal pain, elevated liver function tests (AST, ALT). <span class="typehead">Endocrine:</span> Galactorrhea. <span class="typehead">Metabolic:</span> Hyperglycemia, diabetes mellitus. <span class="typehead">Respiratory:</span> Rhinitis, cough, dyspnea. <span class="typehead">Skin:</span> Photosensitivity. <span class="typehead">Urogenital:</span> Urinary retention, menorrhagia, decreased sexual desire, erectile dysfunction, sexual dysfunction male and female. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Liver function tests (AST, ALT) are elevated.</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Risperidone may enhance the effects of certain <span class="classification">antihypertensive agents</span>. May antagonize the antiparkinson effects of <b>bromocriptine,</b>
<b>cabergoline,</b>
<b>levodopa,</b>
<b>pergolide,</b>
<b>pramipexole,</b>
<b>ropinirole.</b>
<b>Carbamazepine</b> may decrease risperidone levels. <b>Clozapine</b> may increase risperidone levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed; not affected by food. <span class="typehead">Onset:</span> Therapeutic effect 12 wk. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> 0.7 L/kg; in animal studies, risperidone has been found in breast milk. <span class="typehead">Metabolism:</span> Metabolized primarily in liver by cytochrome P450 with an active metabolite, 9-hydroxyrisperidone. <span class="typehead">Elimination:</span> 70% excreted in urine; 14% in feces. <span class="typehead">Half-Life:</span> 20 h for slow metabolizers, 30 h for fast metabolizers. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Reassess patients periodically and maintain on the lowest effective drug dose.</li>
<li>Monitor closely neurologic status of older adults.</li>
<li>Monitor cardiovascular status closely; assess for orthostatic hypotension, especially during initial dosage titration.</li>
<li>Monitor closely those at risk for seizures.</li>
<li>Assess degree of cognitive and motor impairment, and assess for environmental hazards.</li>
<li>Lab tests: Monitor periodically blood glucose, serum electrolytes, liver function, and complete blood counts.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Do not engage in potentially hazardous activities until the response to drug is known.</li>
<li>Be aware of the risk of orthostatic hypotension.</li>
<li>Learn adverse effects and report to physician those that are bothersome.</li>
<li>Wear sunscreen and protective clothing to avoid photosensitivity.</li>
<li>Notify physician if you intend to or become pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>